{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T07:22:39Z","timestamp":1789024959277,"version":"build-2803163510"},"reference-count":118,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Distinguished Scientist Fellowship Program (DSFP) of the King Saud University"},{"name":"Istanbul University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s40266-026-01290-0","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T13:03:19Z","timestamp":1773925399000},"page":"341-360","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Managing Bone Fragility in Older Adults with Diabetes: Pathophysiology, Assessment, and Therapeutic Considerations"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6039-5866","authenticated-orcid":false,"given":"Gulistan","family":"Bahat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8690-0189","authenticated-orcid":false,"given":"Tugba","family":"Erdogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0961-3810","authenticated-orcid":false,"given":"Savas","family":"Ozturk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0732-4764","authenticated-orcid":false,"given":"Ozlem Soyluk","family":"Selcukbiricik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0994-1152","authenticated-orcid":false,"given":"Serdar","family":"Ozkok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0075-6313","authenticated-orcid":false,"given":"Dilek Gogas","family":"Yavuz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9080-404X","authenticated-orcid":false,"given":"Mehmet Akif","family":"Karan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6290-752X","authenticated-orcid":false,"given":"Jean-Yves","family":"Reginster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,19]]},"reference":[{"issue":"4","key":"1290_CR1","volume":"13","author":"I Papaioannou","year":"2021","unstructured":"Papaioannou I, et al. Systematic review: are the elderly with diabetes mellitus type 2 prone to fragility fractures? Cureus. 2021;13(4):e14514.","journal-title":"Cureus"},{"key":"1290_CR2","unstructured":"Federation, I.D. IDF Diabetes Atlas. 11th Edition. 2025. https:\/\/diabetesatlas.org\/resources\/idf-diabetes-atlas-2025\/ Accessed 24 Aug 2025."},{"key":"1290_CR3","unstructured":"National Institute for Health and Care Excellence: guidelines, in osteoporosis: assessing the risk of fragility fracture. 2017, National Institute for Health and Care Excellence (NICE) Copyright \u00a9 NICE 2019.: London."},{"issue":"1","key":"1290_CR4","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s13300-020-00964-1","volume":"12","author":"C Romero-D\u00edaz","year":"2021","unstructured":"Romero-D\u00edaz C, et al. Diabetes and bone fragility. Diabetes Ther. 2021;12(1):71\u201386.","journal-title":"Diabetes Ther"},{"issue":"12","key":"1290_CR5","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1007\/s00198-018-4650-2","volume":"29","author":"SL Ferrari","year":"2018","unstructured":"Ferrari SL, et al. Diagnosis and management of bone fragility in diabetes: an emerging challenge. Osteoporos Int. 2018;29(12):2585\u201396.","journal-title":"Osteoporos Int"},{"key":"1290_CR6","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3389\/fendo.2018.00006","volume":"9","author":"C Marin","year":"2018","unstructured":"Marin C, et al. The impact of type 2 diabetes on bone fracture healing. Front Endocrinol (Lausanne). 2018;9:6.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"4","key":"1290_CR7","doi-asserted-by":"publisher","first-page":"R127","DOI":"10.1530\/EJE-15-0820","volume":"174","author":"FS Hough","year":"2016","unstructured":"Hough FS, et al. Mechanisms in endocrinology: mechanisms and evaluation of bone fragility in type 1 diabetes mellitus. Eur J Endocrinol. 2016;174(4):R127\u201338.","journal-title":"Eur J Endocrinol"},{"key":"1290_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1052592","volume":"13","author":"B Wu","year":"2022","unstructured":"Wu B, et al. A narrative review of diabetic bone disease: characteristics, pathogenesis, and treatment. Front Endocrinol (Lausanne). 2022;13:1052592.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"1290_CR9","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S2213-8587(21)00347-8","volume":"10","author":"LC Hofbauer","year":"2022","unstructured":"Hofbauer LC, et al. Bone fragility in diabetes: novel concepts and clinical implications. Lancet Diabetes Endocrinol. 2022;10(3):207\u201320.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1290_CR10","doi-asserted-by":"publisher","first-page":"100330","DOI":"10.1016\/j.metop.2024.100330","volume":"24","author":"P Sharma","year":"2024","unstructured":"Sharma P, Sharma RK, Gaur K. Understanding the impact of diabetes on bone health: a clinical review. Metabol Open. 2024;24:100330.","journal-title":"Metabol Open"},{"issue":"1","key":"1290_CR11","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1210\/endo-116-1-296","volume":"116","author":"BE Kream","year":"1985","unstructured":"Kream BE, et al. Characterization of the effect of insulin on collagen synthesis in fetal rat bone. Endocrinology. 1985;116(1):296\u2013302.","journal-title":"Endocrinology"},{"issue":"4","key":"1290_CR12","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1097\/MED.0000000000000421","volume":"25","author":"VN Shah","year":"2018","unstructured":"Shah VN, et al. Bone health in type 1 diabetes. Curr Opin Endocrinol Diabetes Obes. 2018;25(4):231\u20136.","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"1290_CR13","unstructured":"Sheffield, U.o. FRAX\u00ae Fracture Risk Assessment Tool. 2025. https:\/\/frax.shef.ac.uk\/FRAX\/tool.aspx?country=9. Accessed 6 Aug 2025."},{"issue":"6","key":"1290_CR14","doi-asserted-by":"publisher","first-page":"706","DOI":"10.4239\/wjd.v12.i6.706","volume":"12","author":"R Palui","year":"2021","unstructured":"Palui R, et al. Critical review of bone health, fracture risk and management of bone fragility in diabetes mellitus. World J Diabetes. 2021;12(6):706\u201329.","journal-title":"World J Diabetes"},{"issue":"15","key":"1290_CR15","doi-asserted-by":"publisher","first-page":"2400","DOI":"10.3390\/nu17152400","volume":"17","author":"N Levran","year":"2025","unstructured":"Levran N, Shalev-Goldman E, Levy-Shraga Y. Bone health in children and adolescents with type 1 diabetes: optimizing bone accrual and preventing fractures. Nutrients. 2025;17(15):2400.","journal-title":"Nutrients"},{"issue":"3","key":"1290_CR16","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.jocd.2017.06.011","volume":"20","author":"C Poiana","year":"2017","unstructured":"Poiana C, Capatina C. Fracture risk assessment in patients with diabetes mellitus. J Clin Densitom. 2017;20(3):432\u201343.","journal-title":"J Clin Densitom"},{"key":"1290_CR17","unstructured":"Sheffield, U.o. FRAX\u00ae Plus. 2025. https:\/\/www.fraxplus.org\/frax-plus. Accessed 6 Aug 2025."},{"issue":"23","key":"1290_CR18","doi-asserted-by":"publisher","first-page":"7399","DOI":"10.3390\/jcm12237399","volume":"12","author":"AI Trandafir","year":"2023","unstructured":"Trandafir AI, et al. Trabecular bone score (TBS) in individuals with type 2 diabetes mellitus: an updated review. J Clin Med. 2023;12(23):7399.","journal-title":"J Clin Med"},{"issue":"2","key":"1290_CR19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0319602","volume":"20","author":"W Su","year":"2025","unstructured":"Su W, et al. Risk factors for osteoporosis in elderly patients with type 2 diabetes: a protocol for systematic review and meta-analysis. PLoS\u00a0One. 2025;20(2):e0319602.","journal-title":"PLoS\u00a0One"},{"key":"1290_CR20","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/7608964","volume":"2020","author":"C Eller-Vainicher","year":"2020","unstructured":"Eller-Vainicher C, et al. Pathophysiology and management of type 2 diabetes mellitus bone fragility. J Diabetes Res. 2020;2020:7608964.","journal-title":"J Diabetes Res"},{"issue":"4","key":"1290_CR21","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1038\/nrendo.2016.153","volume":"13","author":"N Napoli","year":"2017","unstructured":"Napoli N, et al. Mechanisms of diabetes mellitus-induced bone fragility. Nat Rev Endocrinol. 2017;13(4):208\u201319.","journal-title":"Nat Rev Endocrinol"},{"issue":"4","key":"1290_CR22","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1097\/MED.0000000000000645","volume":"28","author":"M Shah","year":"2021","unstructured":"Shah M, et al. Treatment of bone fragility in patients with diabetes: antiresorptive versus anabolic? Curr Opin Endocrinol Diabetes Obes. 2021;28(4):377\u201382.","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"1290_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20194873","author":"CE Murray","year":"2019","unstructured":"Murray CE, Coleman CM. Impact of diabetes mellitus on bone health. Int J Mol Sci. 2019. https:\/\/doi.org\/10.3390\/ijms20194873.","journal-title":"Int J Mol Sci"},{"issue":"9","key":"1290_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0203533","volume":"13","author":"D Mart\u00ednez-Laguna","year":"2018","unstructured":"Mart\u00ednez-Laguna D, et al. Fracture risk in type 2 diabetic patients: a clinical prediction tool based on a large population-based cohort. PLoS\u00a0One. 2018;13(9):e0203533.","journal-title":"PLoS\u00a0One"},{"issue":"1","key":"1290_CR25","doi-asserted-by":"publisher","first-page":"136","DOI":"10.2337\/dc16-2042","volume":"40","author":"R Pop-Busui","year":"2016","unstructured":"Pop-Busui R, et al. Diabetic neuropathy: a position statement by the American Diabetes Association. Diabetes Care. 2016;40(1):136\u201354.","journal-title":"Diabetes Care"},{"issue":"6","key":"1290_CR26","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1007\/s13300-017-0295-y","volume":"8","author":"U Alam","year":"2017","unstructured":"Alam U, et al. Diabetic neuropathy and gait: a review. Diabetes Ther. 2017;8(6):1253\u201364.","journal-title":"Diabetes Ther"},{"key":"1290_CR27","doi-asserted-by":"crossref","unstructured":"KDIGO 2017 Clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone\u00a0disorder (CKD-MBD). Kidney Int Suppl (2011). 2017;7(1):1\u201359.","DOI":"10.1016\/j.kisu.2017.04.001"},{"issue":"10","key":"1290_CR28","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1093\/jbmr\/zjae134","volume":"39","author":"F Johannesdottir","year":"2024","unstructured":"Johannesdottir F, et al. Microvascular disease and early diabetes onset are associated with deficits in femoral neck bone density and structure among older adults with longstanding type 1 diabetes. J Bone Miner Res. 2024;39(10):1454\u201363.","journal-title":"J Bone Miner Res"},{"issue":"1","key":"1290_CR29","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-024067","volume":"9","author":"H Wang","year":"2019","unstructured":"Wang H, et al. Diabetes mellitus and the risk of fractures at specific sites: a meta-analysis. BMJ Open. 2019;9(1):e024067.","journal-title":"BMJ Open"},{"key":"1290_CR30","doi-asserted-by":"publisher","first-page":"455","DOI":"10.2147\/TCRM.S131945","volume":"13","author":"A Moayeri","year":"2017","unstructured":"Moayeri A, et al. Fracture risk in patients with type 2 diabetes mellitus and possible risk factors: a systematic review and meta-analysis. Ther Clin Risk Manag. 2017;13:455\u201368.","journal-title":"Ther Clin Risk Manag"},{"key":"1290_CR31","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s40842-018-0060-9","volume":"4","author":"RJ Valderr\u00e1bano","year":"2018","unstructured":"Valderr\u00e1bano RJ, Linares MI. Diabetes mellitus and bone health: epidemiology, etiology and implications for fracture risk stratification. Clin Diabetes Endocrinol. 2018;4:9.","journal-title":"Clin Diabetes Endocrinol"},{"issue":"4","key":"1290_CR32","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s00198-006-0253-4","volume":"18","author":"P Vestergaard","year":"2007","unstructured":"Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes\u2013a meta-analysis. Osteoporos Int. 2007;18(4):427\u201344.","journal-title":"Osteoporos Int"},{"issue":"5","key":"1290_CR33","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1093\/aje\/kwm106","volume":"166","author":"M Janghorbani","year":"2007","unstructured":"Janghorbani M, et al. Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol. 2007;166(5):495\u2013505.","journal-title":"Am J Epidemiol"},{"issue":"2","key":"1290_CR34","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1002\/jbmr.556","volume":"27","author":"LM Giangregorio","year":"2012","unstructured":"Giangregorio LM, et al. FRAX underestimates fracture risk in patients with diabetes. J Bone Miner Res. 2012;27(2):301\u20138.","journal-title":"J Bone Miner Res"},{"issue":"4","key":"1290_CR35","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1093\/jbmr\/zjaf012","volume":"40","author":"RK Jain","year":"2025","unstructured":"Jain RK, et al. Biases in the performance of FRAX without BMD in predicting fracture risk in a multiethnic population with diabetes: the Diabetes and Aging Study. J Bone Miner Res. 2025;40(4):478\u201391.","journal-title":"J Bone Miner Res"},{"issue":"3","key":"1290_CR36","doi-asserted-by":"publisher","first-page":"339","DOI":"10.3803\/EnM.2018.33.3.339","volume":"33","author":"J Starup-Linde","year":"2018","unstructured":"Starup-Linde J, Hygum K, Langdahl BL. Skeletal fragility in type 2 diabetes mellitus. Endocrinol Metab (Seoul). 2018;33(3):339\u201351.","journal-title":"Endocrinol Metab (Seoul)"},{"issue":"21","key":"1290_CR37","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1001\/jama.2011.715","volume":"305","author":"AV Schwartz","year":"2011","unstructured":"Schwartz AV. Association of BMD and FRAX score with risk of fracture in older adults with type 2 diabetes. JAMA. 2011;305(21):2184\u201392.","journal-title":"JAMA"},{"key":"1290_CR38","doi-asserted-by":"publisher","first-page":"1474546","DOI":"10.3389\/fendo.2024.1474546","volume":"15","author":"C Dehnen","year":"2024","unstructured":"Dehnen C, et al. Quantitative ultrasound imaging reveals distinct fracture-associated differences in tibial intracortical pore morphology and viscoelastic properties in aged individuals with and without diabetes mellitus\u2014an exploratory study. Front Endocrinol. 2024;15:1474546.","journal-title":"Front Endocrinol"},{"issue":"2","key":"1290_CR39","doi-asserted-by":"publisher","first-page":"133","DOI":"10.2174\/1874609816666230109153424","volume":"16","author":"NM Catikkas","year":"2023","unstructured":"Catikkas NM, et al. Prevalence and determinants of falls in community-dwelling older adults in T\u00fcrkiye: a population-based cross-sectional study conducted between 2014-2015. Curr Aging Sci. 2023;16(2):133\u201342.","journal-title":"Curr Aging Sci"},{"key":"1290_CR40","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/342650","volume":"2013","author":"RT Crews","year":"2013","unstructured":"Crews RT, et al. A growing troubling triad: diabetes, aging, and falls. J Aging Res. 2013;2013:342650.","journal-title":"J Aging Res"},{"issue":"1","key":"1290_CR41","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s11657-021-01038-w","volume":"16","author":"G Bahat","year":"2021","unstructured":"Bahat G, et al. The current situation in the approach to osteoporosis in older adults in Turkey: areas in need of improvement with a model for other populations. Arch Osteoporos. 2021;16(1):179.","journal-title":"Arch Osteoporos"},{"issue":"9","key":"1290_CR42","doi-asserted-by":"publisher","first-page":"afac205","DOI":"10.1093\/ageing\/afac205","volume":"51","author":"M Montero-Odasso","year":"2022","unstructured":"Montero-Odasso M, et al. World guidelines for falls prevention and management for older adults: a global initiative. Age Ageing. 2022;51(9):afac205.","journal-title":"Age Ageing"},{"issue":"4","key":"1290_CR43","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1007\/s41999-025-01237-5","volume":"16","author":"LJ Seppala","year":"2025","unstructured":"Seppala LJ, et al. Challenges and opportunities for falls prevention: an online survey across European healthcare professionals. Eur Geriatr Med. 2025;16(4):1269\u201382.","journal-title":"Eur Geriatr Med"},{"issue":"5","key":"1290_CR44","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1503\/cmaj.050051","volume":"173","author":"K Rockwood","year":"2005","unstructured":"Rockwood K, et al. A global clinical measure of fitness and frailty in elderly people. CMAJ. 2005;173(5):489\u201395.","journal-title":"CMAJ"},{"issue":"3","key":"1290_CR45","doi-asserted-by":"publisher","first-page":"M146","DOI":"10.1093\/gerona\/56.3.M146","volume":"56","author":"LP Fried","year":"2001","unstructured":"Fried LP, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56(3):M146\u201356.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"1290_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.exger.2022.111887","volume":"166","author":"G Bahat","year":"2022","unstructured":"Bahat G, et al. Simpler modified Fried Frailty Scale as a practical tool to evaluate physical frailty: methodological report for its cross-cultural adaptation and validation. Exp Gerontol. 2022;166:111887.","journal-title":"Exp Gerontol"},{"issue":"5","key":"1290_CR47","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1007\/s12603-020-1582-2","volume":"25","author":"G Bahat","year":"2021","unstructured":"Bahat G, et al. Success of simpler modified Fried Frailty Scale to predict mortality among nursing home residents. J Nutr Health Aging. 2021;25(5):606\u201310.","journal-title":"J Nutr Health Aging"},{"issue":"1","key":"1290_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.medcli.2025.106958","volume":"165","author":"C Corral Tuesta","year":"2025","unstructured":"Corral Tuesta C, et al. Simpler modified Fried Frailty Scale: translation and validation into Spanish. Med Clin (Barc). 2025;165(1):106958.","journal-title":"Med Clin (Barc)"},{"issue":"1","key":"1290_CR49","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12877-025-05698-y","volume":"25","author":"C K\u00fc\u00e7\u00fck","year":"2025","unstructured":"K\u00fc\u00e7\u00fck C, et al. The simpler modified Fried Frailty Scale predicts 2-year mortality in older adults with heart failure: a pilot study. BMC Geriatr. 2025;25(1):50.","journal-title":"BMC Geriatr"},{"issue":"4","key":"1290_CR50","doi-asserted-by":"publisher","first-page":"531","DOI":"10.4093\/dmj.2024.0310","volume":"48","author":"J-S Yun","year":"2024","unstructured":"Yun J-S, et al. Holistic and personalized strategies for managing in elderly type 2 diabetes patients. Diabetes Metab J. 2024;48(4):531\u201345.","journal-title":"Diabetes Metab J"},{"key":"1290_CR51","unstructured":"Plan, M.H. 2024 American Diabetes Association Annual Standards of Care update. 2024. https:\/\/www.ilmeridian.com\/newsroom\/2024-american-diabetes-association-annual-standards-of-care-upda.html. Accessed 6 Aug 2025."},{"key":"1290_CR52","unstructured":"(ISCD), I.S.f.C.D. Official positions 2023 (adult). 2023. https:\/\/iscd.org\/official-positions-2023\/. Accessed 6 Aug 2025."},{"issue":"10","key":"1290_CR53","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1007\/s00198-021-05900-y","volume":"33","author":"MS LeBoff","year":"2022","unstructured":"LeBoff MS, et al. The clinician\u2019s guide to prevention and treatment of osteoporosis. Osteoporos Int. 2022;33(10):2049\u2013102.","journal-title":"Osteoporos Int"},{"issue":"8","key":"1290_CR54","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1210\/clinem\/dgae290","volume":"109","author":"MB Demay","year":"2024","unstructured":"Demay MB, et al. Vitamin D for the prevention of disease: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2024;109(8):1907\u201347.","journal-title":"J Clin Endocrinol Metab"},{"key":"1290_CR55","unstructured":"Society, E. Bone health and osteoporosis\u2014Clinical practice guidelines. 2020. https:\/\/www.endocrine.org\/clinical-practice-guidelines\/bone-health-and-osteoporosis. Accessed 6 Aug 2025."},{"issue":"7","key":"1290_CR56","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1007\/s00198-010-1285-3","volume":"21","author":"B Dawson-Hughes","year":"2010","unstructured":"Dawson-Hughes B, et al. IOF position statement: vitamin D recommendations for older adults. Osteoporos Int. 2010;21(7):1151\u20134.","journal-title":"Osteoporos Int"},{"issue":"6","key":"1290_CR57","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1056\/NEJMoa1900906","volume":"381","author":"AG Pittas","year":"2019","unstructured":"Pittas AG, et al. Vitamin D supplementation and prevention of type 2 diabetes. N Engl J Med. 2019;381(6):520\u201330.","journal-title":"N Engl J Med"},{"key":"1290_CR58","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-066222","volume":"377","author":"T Kawahara","year":"2022","unstructured":"Kawahara T, et al. Effect of active vitamin D treatment on development of type 2 diabetes: DPVD randomised controlled trial in Japanese population. BMJ. 2022;377:e066222.","journal-title":"BMJ"},{"issue":"3","key":"1290_CR59","doi-asserted-by":"publisher","first-page":"355","DOI":"10.7326\/M22-3018","volume":"176","author":"AG Pittas","year":"2023","unstructured":"Pittas AG, et al. Vitamin D and risk fortype 2 diabetes in people with prediabetes\u202f: a systematic review and meta-analysis of \u0131ndividual participant data from 3 randomized clinical trials. Ann Intern Med. 2023;176(3):355\u201363.","journal-title":"Ann Intern Med"},{"issue":"1","key":"1290_CR60","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s40520-020-01678-x","volume":"33","author":"R Rizzoli","year":"2021","unstructured":"Rizzoli R. Vitamin D supplementation: upper limit for safety revisited? Aging Clin Exp Res. 2021;33(1):19\u201324.","journal-title":"Aging Clin Exp Res"},{"issue":"5","key":"1290_CR61","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1210\/endrev\/bnae009","volume":"45","author":"A Giustina","year":"2024","unstructured":"Giustina A, et al. Consensus statement on vitamin D status assessment and supplementation: whys, whens, and hows. Endocr Rev. 2024;45(5):625\u201354.","journal-title":"Endocr Rev"},{"issue":"4","key":"1290_CR62","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1016\/j.clnu.2017.08.016","volume":"37","author":"SM Robinson","year":"2018","unstructured":"Robinson SM, et al. Does nutrition play a role in the prevention and management of sarcopenia? Clin Nutr. 2018;37(4):1121\u201332.","journal-title":"Clin Nutr"},{"issue":"4","key":"1290_CR63","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s11914-020-00597-0","volume":"18","author":"R Viggers","year":"2020","unstructured":"Viggers R, et al. The \u0131mpact of exercise on bone health in type 2 diabetes mellitus-a systematic review. Curr Osteoporos Rep. 2020;18(4):357\u201370.","journal-title":"Curr Osteoporos Rep"},{"issue":"14","key":"1290_CR64","doi-asserted-by":"publisher","first-page":"8677","DOI":"10.3390\/ijerph19148677","volume":"19","author":"J Sanz-C\u00e1novas","year":"2022","unstructured":"Sanz-C\u00e1novas J, et al. Management of type 2 diabetes mellitus in elderly patients with frailty and\/or sarcopenia. Int J Environ Res Public Health. 2022;19(14):8677.","journal-title":"Int J Environ Res Public Health"},{"issue":"11","key":"1290_CR65","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.2337\/dc16-1728","volume":"39","author":"SR Colberg","year":"2016","unstructured":"Colberg SR, et al. Physical activity\/exercise and diabetes: a position statement of the American Diabetes Association. Diabetes Care. 2016;39(11):2065\u201379.","journal-title":"Diabetes Care"},{"key":"1290_CR66","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1159\/000357342","volume":"60","author":"E Ferriolli","year":"2014","unstructured":"Ferriolli E, Pessanha FP, Marchesi JC. Diabetes and exercise in the elderly. Med Sport Sci. 2014;60:122\u20139.","journal-title":"Med Sport Sci"},{"key":"1290_CR67","unstructured":"American Diabetes Association Professional Practice Committee. 4. Comprehensive medical evaluation and assessment of comorbidities: standards of care in diabetes-2024. Diabetes Care. 2024;47(Suppl 1):S52\u2013S76."},{"key":"1290_CR68","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Professional Practice Committee for Diabetes*; 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes\u20142026. Diabetes Care. 2026;49 (Supplement_1):S27\u2013S49.","DOI":"10.2337\/dc26-S002"},{"key":"1290_CR69","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.diabres.2016.03.009","volume":"115","author":"BN Conway","year":"2016","unstructured":"Conway BN, et al. Glycemic control and fracture risk in elderly patients with diabetes. Diabetes Res Clin Pract. 2016;115:47\u201353.","journal-title":"Diabetes Res Clin Pract"},{"issue":"5","key":"1290_CR70","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1210\/jc.2019-00198","volume":"104","author":"D LeRoith","year":"2019","unstructured":"LeRoith D, et al. Treatment of diabetes in older adults: an Endocrine Society* clinical practice guideline. J Clin Endocrinol Metab. 2019;104(5):1520\u201374.","journal-title":"J Clin Endocrinol Metab"},{"key":"1290_CR71","doi-asserted-by":"crossref","unstructured":"13. Older adults: standards of care in diabetes-2024. Diabetes Care. 2024; 47(Suppl 1):S244\u2013s257.","DOI":"10.2337\/dc24-S013"},{"key":"1290_CR72","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.861422","volume":"13","author":"ZK Al-Mashhadi","year":"2022","unstructured":"Al-Mashhadi ZK, et al. SGLT2 inhibitor treatment is not associated with an increased risk of osteoporotic fractures when compared to GLP-1 receptor agonists: a nationwide cohort study. Front Endocrinol (Lausanne). 2022;13:861422.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"1290_CR73","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s40266-021-00855-5","volume":"38","author":"G Bahat","year":"2021","unstructured":"Bahat G, et al. International validation of the Turkish \u0131nappropriate medication use in the elderly (TIME) criteria set: a Delphi panel study. Drugs Aging. 2021;38(6):513\u201321.","journal-title":"Drugs Aging"},{"key":"1290_CR74","doi-asserted-by":"publisher","DOI":"10.3390\/medicina60030393","author":"A Wikarek","year":"2024","unstructured":"Wikarek A, et al. Effect of drugs used in pharmacotherapy of type 2 diabetes on bone density and risk of bone fractures. Medicina (Kaunas). 2024. https:\/\/doi.org\/10.3390\/medicina60030393.","journal-title":"Medicina (Kaunas)"},{"key":"1290_CR75","first-page":"129","volume":"17","author":"G Deng","year":"2025","unstructured":"Deng G, et al. The role of antidiabetic drugs in bone health: assessing the risk of osteoporosis subtypes and fractures using Mendelian randomization. Orthop Res Rev. 2025;17:129\u201345.","journal-title":"Orthop Res Rev"},{"issue":"6","key":"1290_CR76","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1007\/s00198-023-07013-0","volume":"35","author":"Y Cai","year":"2024","unstructured":"Cai Y, Jun G, Zhuang X. Metformin treatment reduces the incidence of osteoporosis: a two-sample Mendelian randomized study. Osteoporos Int. 2024;35(6):1089\u201398.","journal-title":"Osteoporos Int"},{"issue":"2","key":"1290_CR77","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1210\/er.2012-1042","volume":"36","author":"MP Gilbert","year":"2015","unstructured":"Gilbert MP, Pratley RE. The impact of diabetes and diabetes medications on bone health. Endocr Rev. 2015;36(2):194\u2013213.","journal-title":"Endocr Rev"},{"issue":"3","key":"1290_CR78","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s41999-020-00297-z","volume":"11","author":"G Bahat","year":"2020","unstructured":"Bahat G, et al. Turkish inappropriate medication use in the elderly (TIME) criteria to improve prescribing in older adults: TIME-to-STOP\/TIME-to-START. Eur Geriatr Med. 2020;11(3):491\u20138.","journal-title":"Eur Geriatr Med"},{"issue":"9","key":"1290_CR79","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s40266-023-01049-x","volume":"40","author":"G Bahat","year":"2023","unstructured":"Bahat G, Ozkok S, Petrovic M. Management of type 2 diabetes in frail older adults. Drugs Aging. 2023;40(9):751\u201361.","journal-title":"Drugs Aging"},{"issue":"4","key":"1290_CR80","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1080\/17843286.2021.1952379","volume":"77","author":"G Bahat","year":"2022","unstructured":"Bahat G, et al. Management of type 2 diabetes mellitus in older adults: eight case studies with focus SGLT-2 inhibitors and metformin. Acta Clin Belg. 2022;77(4):727\u201334.","journal-title":"Acta Clin Belg"},{"issue":"1","key":"1290_CR81","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.clnu.2019.10.010","volume":"39","author":"G Bahat","year":"2020","unstructured":"Bahat G, Erdogan T, Karan MA. Need for increased awareness for avoiding metformin treatment in malnourished older adults with diabetes mellitus. Clin Nutr. 2020;39(1):322.","journal-title":"Clin Nutr"},{"key":"1290_CR82","doi-asserted-by":"publisher","DOI":"10.1007\/s41999-025-01168-1","author":"V Boccardi","year":"2025","unstructured":"Boccardi V, et al. Challenges, current innovations, and opportunities for managing type 2 diabetes in frail older adults: a position paper of the European Geriatric Medicine Society (EuGMS)-Special Interest Group in Diabetes. Eur Geriatr Med. 2025. https:\/\/doi.org\/10.1007\/s41999-025-01168-1.","journal-title":"Eur Geriatr Med"},{"key":"1290_CR83","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2019.107990","volume":"159","author":"Z Zhang","year":"2020","unstructured":"Zhang Z, et al. Sulfonylurea and fracture risk in patients with type 2 diabetes mellitus: a meta-analysis. Diabetes Res Clin Pract. 2020;159:107990.","journal-title":"Diabetes Res Clin Pract"},{"issue":"1","key":"1290_CR84","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1186\/s12891-023-06493-9","volume":"24","author":"M Bahardoust","year":"2023","unstructured":"Bahardoust M, et al. The use of metformin, sulfonylurea compounds and insulin and the risk of hip fractures in diabetic patients: a systematic review and meta-analysis of observational studies. BMC Musculoskelet Disord. 2023;24(1):367.","journal-title":"BMC Musculoskelet Disord"},{"issue":"3","key":"1290_CR85","first-page":"393","volume":"60","author":"A Wikarek","year":"2024","unstructured":"Wikarek A, et al. Effect of drugs used in pharmacotherapy of type 2 diabetes on bone density and risk of bone fractures. Med Kaunas. 2024;60(3):393.","journal-title":"Med Kaunas"},{"key":"1290_CR86","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1357309","volume":"16","author":"HF Azhari","year":"2025","unstructured":"Azhari HF, Dawson J. Clinical implications of fracture severity risk with pioglitazone: a systematic review and meta-analysis of clinical randomized trials. Front Pharmacol. 2025;16:1357309.","journal-title":"Front Pharmacol"},{"issue":"11","key":"1290_CR87","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.2337\/dc11-1099","volume":"34","author":"M Monami","year":"2011","unstructured":"Monami M, et al. Dipeptidyl peptidase-4 inhibitors and bone fractures: a meta-analysis of randomized clinical trials. Diabetes Care. 2011;34(11):2474\u20136.","journal-title":"Diabetes Care"},{"key":"1290_CR88","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.735824","volume":"12","author":"YS Zhang","year":"2021","unstructured":"Zhang YS, et al. Effects of anti-diabetic drugs on fracture risk: a systematic review and network meta-analysis. Front Endocrinol (Lausanne). 2021;12:735824.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1290_CR89","doi-asserted-by":"publisher","first-page":"3361309","DOI":"10.1155\/2021\/3361309","volume":"2021","author":"TT Cai","year":"2021","unstructured":"Cai TT, et al. Effects of GLP-1 receptor agonists on bone mineral density in patients with type 2 diabetes mellitus: a 52-week clinical study. Biomed Res Int. 2021;2021:3361309.","journal-title":"Biomed Res Int"},{"issue":"12","key":"1290_CR90","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.1007\/s00198-018-4649-8","volume":"29","author":"YS Zhang","year":"2018","unstructured":"Zhang YS, et al. Glucagon-like peptide-1 receptor agonists and fracture risk: a network meta-analysis of randomized clinical trials. Osteoporos Int. 2018;29(12):2639\u201344.","journal-title":"Osteoporos Int"},{"key":"1290_CR91","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102624","volume":"72","author":"MS Hansen","year":"2024","unstructured":"Hansen MS, et al. Once-weekly semaglutide versus placebo in adults with increased fracture risk: a randomised, double-blinded, two-centre, phase 2 trial. EClinicalMedicine. 2024;72:102624.","journal-title":"EClinicalMedicine"},{"issue":"1","key":"1290_CR92","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1210\/jc.2015-3167","volume":"101","author":"NB Watts","year":"2016","unstructured":"Watts NB, et al. Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2016;101(1):157\u201366.","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"1290_CR93","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.2337\/dc17-1525","volume":"41","author":"S Kohler","year":"2018","unstructured":"Kohler S, et al. Analysis of fractures in patients with type 2 diabetes treated with empagliflozin in pooled data from placebo-controlled trials and a head-to-head study versus glimepiride. Diabetes Care. 2018;41(8):1809\u201316.","journal-title":"Diabetes Care"},{"key":"1290_CR94","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.3389\/fphar.2018.01517","volume":"9","author":"Y Ye","year":"2018","unstructured":"Ye Y, et al. Effect of sodium-glucose co-transporter 2 \u0131nhibitors on bone metabolism and fracture risk. Front Pharmacol. 2018;9:1517.","journal-title":"Front Pharmacol"},{"issue":"5","key":"1290_CR95","first-page":"3957","volume":"17","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, et al. Insulin use and fracture risk in patients with type 2 diabetes: a meta-analysis of 138,690 patients. Exp Ther Med. 2019;17(5):3957\u201364.","journal-title":"Exp Ther Med"},{"issue":"9","key":"1290_CR96","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.2337\/dc20-0316","volume":"43","author":"AK Lee","year":"2020","unstructured":"Lee AK, et al. Severe hypoglycemia and risk of falls in type 2 diabetes: the Atherosclerosis Risk in Communities (ARIC) study. Diabetes Care. 2020;43(9):2060\u20135.","journal-title":"Diabetes Care"},{"issue":"2","key":"1290_CR97","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s00198-017-4276-9","volume":"29","author":"K Ruppert","year":"2018","unstructured":"Ruppert K, et al. The effect of insulin on bone mineral density among women with type 2 diabetes: a SWAN pharmacoepidemiology study. Osteoporos Int. 2018;29(2):347\u201354.","journal-title":"Osteoporos Int"},{"issue":"11","key":"1290_CR98","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1055\/a-2295-9335","volume":"56","author":"YX Yang","year":"2024","unstructured":"Yang YX, Jin Y. Clinical efficacy of bisphosphonates in treating osteoporosis in diabetes patients: a meta-analysis. Horm Metab Res. 2024;56(11):795\u2013806.","journal-title":"Horm Metab Res"},{"issue":"1","key":"1290_CR99","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s12902-022-01010-w","volume":"22","author":"J Kim","year":"2022","unstructured":"Kim J, et al. Efficacy of bisphosphonate therapy on postmenopausal osteoporotic women with and without diabetes: a prospective trial. BMC Endocr Disord. 2022;22(1):99.","journal-title":"BMC Endocr Disord"},{"issue":"1","key":"1290_CR100","doi-asserted-by":"publisher","first-page":"39","DOI":"10.4140\/TCP.n.2013.39","volume":"28","author":"RL Dunn","year":"2013","unstructured":"Dunn RL, et al. Use of bisphosphonates in older adults: how long is long enough? Consult Pharm. 2013;28(1):39\u201357.","journal-title":"Consult Pharm"},{"issue":"1","key":"1290_CR101","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3803\/EnM.2024.2125","volume":"40","author":"J Ha","year":"2025","unstructured":"Ha J, et al. Long-term efficacy and safety of denosumab: \u0131nsights beyond 10 years of use. Endocrinol Metab (Seoul). 2025;40(1):47\u201356.","journal-title":"Endocrinol Metab (Seoul)"},{"issue":"2","key":"1290_CR102","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.54734","volume":"7","author":"HK Huang","year":"2024","unstructured":"Huang HK, et al. Denosumab and the risk of diabetes in patients treated for osteoporosis. JAMA Netw Open. 2024;7(2):e2354734.","journal-title":"JAMA Netw Open"},{"issue":"1","key":"1290_CR103","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1080\/21556660.2021.1989194","volume":"10","author":"BT Pacheco-Soto","year":"2021","unstructured":"Pacheco-Soto BT, et al. Denosumab improves glucose parameters in patients with impaired glucose tolerance: a systematic review and meta-analysis. J Drug Assess. 2021;10(1):97\u2013105.","journal-title":"J Drug Assess"},{"issue":"12","key":"1290_CR104","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1002\/jbmr.1800","volume":"27","author":"C Cipriani","year":"2012","unstructured":"Cipriani C, Irani D, Bilezikian JP. Safety of osteoanabolic therapy: a decade of experience. J Bone Miner Res. 2012;27(12):2419\u201328.","journal-title":"J Bone Miner Res"},{"key":"1290_CR105","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1558560","volume":"16","author":"L Chen","year":"2025","unstructured":"Chen L, Ji B, Xia C. Efficacy and safety of abaloparatide, denosumab, teriparatide, oral bisphosphonates, and intravenous bisphosphonates in the treatment of male osteoporosis: a systematic review and Bayesian network meta-analysis. Front Endocrinol (Lausanne). 2025;16:1558560.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"1290_CR106","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.eprac.2024.10.017","volume":"31","author":"L Tabatabai","year":"2025","unstructured":"Tabatabai L, et al. Comparative effectiveness of abaloparatide and teriparatide in women 50 years of age and older: update of a real-world retrospective analysis. Endocr Pract. 2025;31(2):159\u201368.","journal-title":"Endocr Pract"},{"issue":"10","key":"1290_CR107","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1097\/01.NURSE.0000545013.60672.65","volume":"48","author":"DA Hussar","year":"2018","unstructured":"Hussar DA. New drugs 2018, Part 3. Nursing. 2018;48(10):32\u201343.","journal-title":"Nursing"},{"key":"1290_CR108","unstructured":"Florent Elefteriou, S.S. Osteoporosis. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK585139\/. Accessed 6 Aug 2025."},{"issue":"1","key":"1290_CR109","doi-asserted-by":"publisher","first-page":"32","DOI":"10.4103\/ijem.ijem_81_24","volume":"29","author":"H Durgia","year":"2025","unstructured":"Durgia H, et al. Role of anabolic anti-osteoporosis therapy in diabetes subjects. Indian J Endocrinol Metab. 2025;29(1):32\u20138.","journal-title":"Indian J Endocrinol Metab"},{"key":"1290_CR110","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.jot.2024.07.011","volume":"48","author":"RMY Wong","year":"2024","unstructured":"Wong RMY, et al. Treatment effects, adverse outcomes and cardiovascular safety of romosozumab\u2014existing worldwide data: a systematic review and meta-analysis. J Orthop Translat. 2024;48:107\u201322.","journal-title":"J Orthop Translat"},{"issue":"5","key":"1290_CR111","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1007\/s00774-024-01531-5","volume":"42","author":"T Kobayashi","year":"2024","unstructured":"Kobayashi T, et al. Efficacy and safety of romosozumab: a meta-analysis of placebo-controlled trials. J Bone Miner Metab. 2024;42(5):492\u2013502.","journal-title":"J Bone Miner Metab"},{"key":"1290_CR112","unstructured":"(CADTH), C.A.f.D.a.T.i.H., Romosozumab (Evenity): CADTH reimbursement review: therapeutic area: osteoporosis. 2022, CADTH: Ottawa (ON)."},{"issue":"10","key":"1290_CR113","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1093\/jbmr\/zjae119","volume":"39","author":"F Cosman","year":"2024","unstructured":"Cosman F, et al. Goal-directed osteoporosis treatment: ASBMR\/BHOF task force position statement 2024. J Bone Miner Res. 2024;39(10):1393\u2013405.","journal-title":"J Bone Miner Res"},{"key":"1290_CR114","unstructured":"\u015eahin T\u0131rnova SZ, EP, Fetullaho\u011flu Durmu\u015f Z, Ozkok S, Erdo\u011fan T, Ozturk S, Soyluk Sel\u00e7ukbiricik O, Yenido\u011fan Yal\u0131n G, G\u00fcl N, Artan AS, Karan MA, Bahat G. Older patients with osteoporosis and chronic kidney disease-mineral and bone disorder (CKD-MBD): a series of challenging cases. In World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO). 2025. Rome, Italy: Abstract Book of the ESCEO 2025 Congress."},{"issue":"4","key":"1290_CR115","doi-asserted-by":"publisher","first-page":"3662","DOI":"10.3892\/mmr.2016.5729","volume":"14","author":"XK Hu","year":"2016","unstructured":"Hu XK, et al. Liraglutide attenuates the osteoblastic differentiation of MC3T3-E1 cells by modulating AMPK\/mTOR signaling. Mol Med Rep. 2016;14(4):3662\u20138.","journal-title":"Mol Med Rep"},{"issue":"4","key":"1290_CR116","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1097\/MED.0000000000000915","volume":"32","author":"O Laohajaroensombat","year":"2025","unstructured":"Laohajaroensombat O, Poochanasri M, Samakkarnthai P. An update on bone in diabetes. Curr Opin Endocrinol Diabetes Obes. 2025;32(4):142\u20138.","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"11","key":"1290_CR117","doi-asserted-by":"publisher","DOI":"10.1002\/jbm4.10833","volume":"7","author":"RC Bunn","year":"2023","unstructured":"Bunn RC, et al. Pharmacologic \u0131nhibition of myostatin with a myostatin antibody \u0131mproves the skeletal muscle and bone phenotype of male \u0131nsulin-deficient diabetic mice. JBMR Plus. 2023;7(11):e10833.","journal-title":"JBMR Plus"},{"issue":"1","key":"1290_CR118","doi-asserted-by":"publisher","first-page":"102","DOI":"10.2337\/dc18-1486","volume":"42","author":"WA Davis","year":"2018","unstructured":"Davis WA, et al. Development and validation of a simple hip fracture risk prediction tool for type 2 diabetes: the Fremantle Diabetes Study phase I. Diabetes Care. 2018;42(1):102\u20139.","journal-title":"Diabetes Care"}],"container-title":["Drugs & Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-026-01290-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40266-026-01290-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-026-01290-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T15:03:25Z","timestamp":1774969405000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40266-026-01290-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,19]]},"references-count":118,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["1290"],"URL":"https:\/\/doi.org\/10.1007\/s40266-026-01290-0","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,19]]},"assertion":[{"value":"15 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"GB: conceptualization, methodology, writing\u2014original draft preparation, writing\u2014reviewing and editing, and supervision; TE: writing\u2014original draft preparation and writing\u2014reviewing and editing; Savas Ozturk: writing\u2014original draft preparation and writing\u2014reviewing and editing; OSS: writing\u2014reviewing and editing; Serdar Ozkok: writing\u2014reviewing and editing; DGY: writing\u2014reviewing and editing; MAK: writing\u2014reviewing and editing and supervision; JYR: writing\u2014reviewing and editing.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"The authors declare that they have no potential conflicts of interest that might be relevant to the contents of this manuscript. G\u00fclistan Bahat and Jean-Yves Reginster are Editorial Board members of\n                      Drugs & Aging\n                      . G\u00fclistan Bahat and Jean-Yves Reginster were not involved in the selection of peer reviewers for the manuscript or any of the subsequent editorial decisions.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable (this manuscript does not contain any individual person\u2019s data in any form).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable (this is a review article based on previously published data and does not involve new studies on human participants or animals).","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable (this manuscript does not contain any individual person\u2019s data in any form).","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable (data sources are cited within the text and reference list).","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}}]}}